Cellebrite DI (NASDAQ:CLBT) Sets New 1-Year Low – Time to Sell?

Cellebrite DI Ltd. (NASDAQ:CLBT)’s stock price reached a new 52-week low on Monday . The company traded as low as $12.34 and last traded at $12.3090, with a volume of 729522 shares trading hands. The stock had previously closed at $13.16.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on CLBT shares. Lake Street Capital increased their price target on shares of Cellebrite DI from $22.00 to $23.00 and gave the company a “buy” rating in a report on Thursday, November 13th. Bank of America upped their price objective on Cellebrite DI from $24.00 to $25.00 and gave the company a “buy” rating in a research report on Thursday, November 13th. Wall Street Zen downgraded Cellebrite DI from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. JPMorgan Chase & Co. boosted their price target on Cellebrite DI from $23.00 to $24.00 and gave the stock an “overweight” rating in a research note on Thursday, November 13th. Finally, Needham & Company LLC lowered their price target on Cellebrite DI from $24.00 to $18.00 and set a “buy” rating on the stock in a report on Thursday, February 12th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Cellebrite DI currently has a consensus rating of “Moderate Buy” and an average target price of $22.50.

Cellebrite DI Stock Performance

The firm has a market cap of $2.85 billion, a P/E ratio of 38.37, a P/E/G ratio of 2.02 and a beta of 1.28. The business’s 50-day simple moving average is $16.59 and its 200 day simple moving average is $17.03.

Cellebrite DI (NASDAQ:CLBT) last released its quarterly earnings results on Wednesday, February 11th. The company reported $0.14 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.14. Cellebrite DI had a return on equity of 20.43% and a net margin of 16.47%.The firm had revenue of $128.82 million for the quarter, compared to the consensus estimate of $126.07 million. During the same period last year, the business posted $0.10 EPS. The company’s revenue for the quarter was up 28.8% on a year-over-year basis. As a group, equities research analysts expect that Cellebrite DI Ltd. will post 0.3 EPS for the current year.

Institutional Investors Weigh In On Cellebrite DI

Several hedge funds and other institutional investors have recently made changes to their positions in CLBT. Financial Management Professionals Inc. purchased a new position in shares of Cellebrite DI in the third quarter worth approximately $28,000. CWM LLC raised its position in Cellebrite DI by 85.7% in the third quarter. CWM LLC now owns 1,560 shares of the company’s stock worth $29,000 after acquiring an additional 720 shares during the period. PNC Financial Services Group Inc. raised its position in Cellebrite DI by 1,998.0% in the second quarter. PNC Financial Services Group Inc. now owns 2,098 shares of the company’s stock worth $34,000 after acquiring an additional 1,998 shares during the period. Towarzystwo Funduszy Inwestycyjnych PZU SA boosted its stake in shares of Cellebrite DI by 81.0% during the 4th quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 1,900 shares of the company’s stock worth $34,000 after acquiring an additional 850 shares during the last quarter. Finally, Toth Financial Advisory Corp bought a new stake in shares of Cellebrite DI during the 3rd quarter valued at $38,000. Hedge funds and other institutional investors own 45.88% of the company’s stock.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.